179 related articles for article (PubMed ID: 33215763)
21. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
22. [Clinical tolerance of high-dose methotrexate used in consolidation therapy in children with acute lymphoblastic leukemia].
Cwiklińska M; Balwierz W; Stanuch H
Przegl Lek; 2010; 67(6):355-60. PubMed ID: 21344761
[TBL] [Abstract][Full Text] [Related]
23. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia.
Donelli MG; Zucchetti M; Robatto A; Perlangeli V; D'Incalci M; Masera G; Rossi MR
Med Pediatr Oncol; 1995 Mar; 24(3):154-9. PubMed ID: 7838036
[TBL] [Abstract][Full Text] [Related]
25. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
[TBL] [Abstract][Full Text] [Related]
26. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
[TBL] [Abstract][Full Text] [Related]
27. The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients.
Traivaree C; Likasitthananon N; Monsereenusorn C; Rujkijyanont P
Cancer Manag Res; 2018; 10():4471-4478. PubMed ID: 30349379
[TBL] [Abstract][Full Text] [Related]
28. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
29. CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: High-dose methotrexate versus cranial irradiation.
Nathan PC; Maze R; Spiegler B; Greenberg ML; Weitzman S; Hitzler JK
Pediatr Blood Cancer; 2004 Jan; 42(1):24-9. PubMed ID: 14752790
[TBL] [Abstract][Full Text] [Related]
30. Acute kidney injury and delayed methotrexate clearance in an adult patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia treated with imatinib.
Chen C; Qi J; Li X; Yongjing W
Eur J Hosp Pharm; 2023 Sep; 30(5):e28. PubMed ID: 36732034
[TBL] [Abstract][Full Text] [Related]
31. Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen.
Kroll M; Kaupat-Bleckmann K; Mörickel A; Altenl J; Schewel DM; Stanullal M; Zimmermann M; Schrappe M; Cario G
Haematologica; 2020 Apr; 105(4):1013-1020. PubMed ID: 31371414
[TBL] [Abstract][Full Text] [Related]
32. Dose-individualization Efficiently Maintains Sufficient Exposure to Methotrexate without Additional Toxicity in High-dose Methotrexate Regimens for Pediatric Acute Lymphoblastic Leukemia.
Shen YQ; Wang ZJ; Wu XY; Li K; Wang ZJ; Xu WF; Zhou F; Jin RM
Curr Med Sci; 2022 Aug; 42(4):769-777. PubMed ID: 35864414
[TBL] [Abstract][Full Text] [Related]
33. Low Serum Albumin Level Is a Risk Factor for Delayed Methotrexate Elimination in High-Dose Methotrexate Treatment.
Kataoka T; Sakurashita H; Kajikawa K; Saeki Y; Taogoshi T; Matsuo H
Ann Pharmacother; 2021 Oct; 55(10):1195-1202. PubMed ID: 33543634
[TBL] [Abstract][Full Text] [Related]
34. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
35. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole.
Yang CH; Yang LJ; Jaing TH; Chan HL
Int J Dermatol; 2000 Aug; 39(8):621-3. PubMed ID: 10971734
[TBL] [Abstract][Full Text] [Related]
36. Hypoalbuminemia and not undernutrition predicts high-dose methotrexate-induced nephrotoxicity in children with acute lymphoblastic leukemia in resource-constrained centers.
Khera S; Sharma G; Negi V; Shaw SC
Pediatr Blood Cancer; 2022 Sep; 69(9):e29738. PubMed ID: 35451162
[TBL] [Abstract][Full Text] [Related]
37. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
[TBL] [Abstract][Full Text] [Related]
38. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
39. Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate.
Harris RD; Bernhardt MB; Zobeck MC; Taylor OA; Gramatges MM; Schafer ES; Lupo PJ; Rabin KR; Scheurer ME; Brown AL
Cancer; 2023 Apr; 129(8):1287-1294. PubMed ID: 36692972
[TBL] [Abstract][Full Text] [Related]
40. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.
Vaishnavi K; Bansal D; Trehan A; Jain R; Attri SV
Pediatr Blood Cancer; 2018 Dec; 65(12):e27241. PubMed ID: 29768710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
